X0306 4 2018-07-31 1 0001488613 Foundation Medicine, Inc. FMI 0001033516 DOUGHERTY MICHAEL R C/O FOUNDATION MEDICINE, INC. 150 SECOND STREET CAMBRIDGE MA 02141 1 0 0 0 Common Stock 2018-07-31 4 U 0 12120 137.00 D 12669 D Common Stock 2018-07-31 4 J 0 12669 137.00 D 0 D Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. The amount reported represents the number of restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such restricted stock units, without interest and less any required withholding taxes. The restricted stock units were granted on October 26, 2016 and vest in three annual installments or immediately upon a change-of-control of the Issuer. /s/ Robert W. Hesslein, as Attorney-in-Fact for Michael R. Dougherty 2018-08-02